{"transactions":[{"id":2651,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:17.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7657,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001140361-26-035615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035615/form4.xml","form_type":"4"}},{"id":2650,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:17.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14461,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001140361-26-035615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035615/form4.xml","form_type":"4"}},{"id":2649,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:17.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10370,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001140361-26-035615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035615/form4.xml","form_type":"4"}},{"id":2648,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:17.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":23.6,"expiration_date":"2033-08-17","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001140361-26-035615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035615/form4.xml","form_type":"4"}},{"id":2647,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-09-03T20:39:17.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035615","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035615/form4.xml","form_type":"4"}},{"id":704829,"issuer":{"id":4644,"kind":"organization","name":"Freenome, Inc.","symbol":"FRNM"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Class B Ordinary Shares","published_at":"2026-07-22T23:21:28.000Z","date":"2026-07-20","kind":"exercise","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. (\"Old Freenome\"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the \"BCA\"), on July 20, 2026 (the \"Closing Date\"), the Issuer consummated its business combination with Old Freenome (the \"Business Combination\"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. (\"Old Freenome\"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the \"BCA\"), on July 20, 2026 (the \"Closing Date\"), the Issuer consummated its business combination with Old Freenome (the \"Business Combination\"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. (\"Old Freenome\"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the \"BCA\"), on July 20, 2026 (the \"Closing Date\"), the Issuer consummated its business combination with Old Freenome (the \"Business Combination\"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. (\"Old Freenome\"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the \"BCA\"), on July 20, 2026 (the \"Closing Date\"), the Issuer consummated its business combination with Old Freenome (the \"Business Combination\"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001749623-26-000003","document":"form4-07222026_110724.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2017526/000174962326000003/form4-07222026_110724.xml","form_type":"4"}},{"id":704828,"issuer":{"id":4644,"kind":"organization","name":"Freenome, Inc.","symbol":"FRNM"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock","published_at":"2026-07-22T23:21:28.000Z","date":"2026-07-20","kind":"exercise","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. (\"Old Freenome\"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the \"BCA\"), on July 20, 2026 (the \"Closing Date\"), the Issuer consummated its business combination with Old Freenome (the \"Business Combination\"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001749623-26-000003","document":"form4-07222026_110724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017526/000174962326000003/form4-07222026_110724.xml","form_type":"4"}},{"id":741149,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:03:09.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":7657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":7657,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001104659-26-073060","document":"tm2617578-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749623/000110465926073060/tm2617578-5_4seq1.xml","form_type":"4"}},{"id":758404,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:55:16.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":8026,"derivative":{"exercise_price":72.51,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":8026},"source":{"system":"sec-edgar","filing":"0001636282-26-000065","document":"wk-form4_1780091713.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000065/wk-form4_1780091713.xml","form_type":"4"}},{"id":942361,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-01-10T00:33:22.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All the shares underlying the option will vest on January 2, 2027, the one-year anniversary of vesting start date, subject to the Reporting Person's continued service through such date."}],"balance_after":15300,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001193125-26-009269","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009269/ownership.xml","form_type":"4"}},{"id":942360,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-10T00:33:22.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2026 for no consideration."}],"balance_after":10360,"source":{"system":"sec-edgar","filing":"0001193125-26-009269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009269/ownership.xml","form_type":"4"}},{"id":1070334,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Class B ordinary shares","published_at":"2025-08-11T21:01:51.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-074368","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025074368/ownership.xml","form_type":"4"}},{"id":1070333,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock","published_at":"2025-08-11T21:01:51.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001213900-25-074368","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025074368/ownership.xml","form_type":"4"}},{"id":1104546,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-21T00:04:24.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":14461,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001104659-25-061276","document":"tm2518364-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749623/000110465925061276/tm2518364-5_4seq1.xml","form_type":"4"}},{"id":1127182,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:36:29.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":15.55,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001636282-25-000066","document":"wk-form4_1748896579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000066/wk-form4_1748896579.xml","form_type":"4"}},{"id":1306922,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-01-08T23:08:10.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/3 of the shares underlying the option will vest on January 6, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for two years, subject to the Reporting Person's continued service through each such date."}],"balance_after":32500,"derivative":{"exercise_price":25.85,"expiration_date":"2035-01-06","underlying":"Ordinary Shares","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0000950170-25-003566","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025003566/ownership.xml","form_type":"4"}},{"id":1306921,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-01-08T23:08:10.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":6960,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2025 for no consideration."}],"balance_after":6960,"source":{"system":"sec-edgar","filing":"0000950170-25-003566","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025003566/ownership.xml","form_type":"4"}},{"id":1330441,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-16T11:00:10.000Z","date":"2024-12-12","kind":"purchase","planned":false,"acquired":true,"shares":12500,"price":49.85,"value":623125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $49.6275 to $50.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001104659-24-128588","document":"tm2430955-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1749623/000110465924128588/tm2430955-2_4seq1.xml","form_type":"4"}},{"id":1330440,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-16T11:00:10.000Z","date":"2024-12-12","kind":"purchase","planned":false,"acquired":true,"shares":7500,"price":49.02,"value":367650.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $48.50 to $49.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001104659-24-128588","document":"tm2430955-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749623/000110465924128588/tm2430955-2_4seq1.xml","form_type":"4"}},{"id":1451331,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-07-19T20:31:03.000Z","date":"2024-07-17","kind":"grant","planned":false,"acquired":true,"shares":72500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of the shares underlying the option will vest on July 17, 2025, the one-year anniversay of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for two years, subject to the Reporting Person's continued service through each such date."}],"balance_after":72500,"derivative":{"exercise_price":18.81,"expiration_date":"2034-07-17","underlying":"Ordinary Shares","underlying_shares":72500},"source":{"system":"sec-edgar","filing":"0000950170-24-084945","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024084945/ownership.xml","form_type":"4"}},{"id":1486042,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-08T00:05:08.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":10370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":10370,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001104659-24-069798","document":"tm2416491-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749623/000110465924069798/tm2416491-6_4seq1.xml","form_type":"4"}},{"id":1658134,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-05T22:29:40.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 40,000 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments beginning on February 1, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":25.86,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-011369","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017024011369/ownership.xml","form_type":"4"}},{"id":1800415,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-21T20:06:29.000Z","date":"2023-08-17","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 100,000 shares of the Issuer's common stock, which will vest in thirty-six equal monthly installments over a three-year period from the date of grant, contingent upon approval of the option at the Issuer's 2024 Annual Meeting of Stockholders and subject to the Reporting Person's continued service to the Issuer."}],"balance_after":150000,"derivative":{"exercise_price":23.6,"expiration_date":"2033-08-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-23-093913","document":"tm2324209-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1749623/000110465923093913/tm2324209-2_4seq1.xml","form_type":"4"}},{"id":1800414,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-21T20:06:29.000Z","date":"2023-08-17","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 50,000 shares of the Issuer's common stock, which will vest in thirty-six equal monthly installments over a three-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":50000,"derivative":{"exercise_price":23.6,"expiration_date":"2033-08-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-23-093913","document":"tm2324209-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749623/000110465923093913/tm2324209-2_4seq1.xml","form_type":"4"}},{"id":1851262,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:00:25.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":128930,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":110.2,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":128930},"source":{"system":"sec-edgar","filing":"0000899243-23-015760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000089924323015760/doc4.xml","form_type":"4"}},{"id":1851261,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:00:25.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":246639,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":29.56,"expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":246639},"source":{"system":"sec-edgar","filing":"0000899243-23-015760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000089924323015760/doc4.xml","form_type":"4"}},{"id":1851260,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:00:25.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":290000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":36.32,"expiration_date":"2031-11-13","underlying":"Common Stock","underlying_shares":290000},"source":{"system":"sec-edgar","filing":"0000899243-23-015760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000089924323015760/doc4.xml","form_type":"4"}},{"id":1851259,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:00:25.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":566307,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":6.7,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":566307},"source":{"system":"sec-edgar","filing":"0000899243-23-015760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000089924323015760/doc4.xml","form_type":"4"}},{"id":1851258,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:00:25.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":481725,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":3.7,"expiration_date":"2030-12-17","underlying":"Common Stock","underlying_shares":481725},"source":{"system":"sec-edgar","filing":"0000899243-23-015760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000089924323015760/doc4.xml","form_type":"4"}},{"id":1851257,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:00:25.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":3.1,"expiration_date":"2030-08-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-015760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000089924323015760/doc4.xml","form_type":"4"}},{"id":1851256,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:00:25.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":132741,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":1.7,"expiration_date":"2030-05-04","underlying":"Common Stock","underlying_shares":132741},"source":{"system":"sec-edgar","filing":"0000899243-23-015760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000089924323015760/doc4.xml","form_type":"4"}},{"id":1851255,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:00:25.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":161105,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":2.9,"expiration_date":"2029-11-06","underlying":"Common Stock","underlying_shares":161105},"source":{"system":"sec-edgar","filing":"0000899243-23-015760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000089924323015760/doc4.xml","form_type":"4"}},{"id":1851254,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Common Stock","published_at":"2023-06-16T16:00:25.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":178098,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 37,113 restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-015760","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000089924323015760/doc4.xml","form_type":"4"}},{"id":1869001,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T19:13:46.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":false,"shares":3,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents an exercise and hold of stock options by the Reporting Person for tax planning purposes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vested and became exercisable on March 27, 2021, and 1/48th of the shares subject to the option vesting monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date."}],"balance_after":132741,"derivative":{"exercise_price":1.7,"expiration_date":"2030-05-04","underlying":"Common Stock","underlying_shares":3},"source":{"system":"sec-edgar","filing":"0001209191-23-034050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123034050/doc4.xml","form_type":"4"}},{"id":1869000,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T19:13:46.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":false,"shares":122528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents an exercise and hold of stock options by the Reporting Person for tax planning purposes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option vesting monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date."}],"balance_after":161105,"derivative":{"exercise_price":2.9,"expiration_date":"2029-11-06","underlying":"Common Stock","underlying_shares":122528},"source":{"system":"sec-edgar","filing":"0001209191-23-034050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123034050/doc4.xml","form_type":"4"}},{"id":1868999,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-06-02T19:13:46.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":true,"shares":3,"price":1.7,"value":5.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents an exercise and hold of stock options by the Reporting Person for tax planning purposes."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a total of 361 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":178036,"source":{"system":"sec-edgar","filing":"0001209191-23-034050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123034050/doc4.xml","form_type":"4"}},{"id":1868998,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-06-02T19:13:46.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":true,"shares":122528,"price":2.9,"value":355331.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents an exercise and hold of stock options by the Reporting Person for tax planning purposes."}],"balance_after":177672,"source":{"system":"sec-edgar","filing":"0001209191-23-034050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123034050/doc4.xml","form_type":"4"}},{"id":1945683,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T21:02:53.000Z","date":"2023-03-15","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option vesting monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date."}],"balance_after":283633,"derivative":{"exercise_price":2.9,"expiration_date":"2029-11-06","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-019948","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123019948/doc4.xml","form_type":"4"}},{"id":1945682,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-03-17T21:02:53.000Z","date":"2023-03-15","kind":"sale","acquired":false,"shares":25000,"price":116.14,"value":2903500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":55144,"source":{"system":"sec-edgar","filing":"0001209191-23-019948","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123019948/doc4.xml","form_type":"4"}},{"id":1945681,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-03-17T21:02:53.000Z","date":"2023-03-15","kind":"exercise","acquired":true,"shares":25000,"price":2.9,"value":72500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."}],"balance_after":80144,"source":{"system":"sec-edgar","filing":"0001209191-23-019948","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123019948/doc4.xml","form_type":"4"}},{"id":1971305,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T21:30:57.000Z","date":"2023-03-03","kind":"exercise","acquired":false,"shares":10620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vested and became exercisable on November 5, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date."}],"balance_after":481725,"derivative":{"exercise_price":3.7,"expiration_date":"2030-12-17","underlying":"Common Stock","underlying_shares":10620},"source":{"system":"sec-edgar","filing":"0001209191-23-016105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123016105/doc4.xml","form_type":"4"}},{"id":1971304,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T21:30:57.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vested and became exercisable on November 5, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date."}],"balance_after":492345,"derivative":{"exercise_price":3.7,"expiration_date":"2030-12-17","underlying":"Common Stock","underlying_shares":700},"source":{"system":"sec-edgar","filing":"0001209191-23-016105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123016105/doc4.xml","form_type":"4"}},{"id":1971303,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-03-03T21:30:57.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":10620,"price":125.13,"value":1328880.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":55144,"source":{"system":"sec-edgar","filing":"0001209191-23-016105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123016105/doc4.xml","form_type":"4"}},{"id":1971302,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-03-03T21:30:57.000Z","date":"2023-03-03","kind":"exercise","acquired":true,"shares":10620,"price":3.7,"value":39294.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."}],"balance_after":65764,"source":{"system":"sec-edgar","filing":"0001209191-23-016105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123016105/doc4.xml","form_type":"4"}},{"id":1971301,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-03-03T21:30:57.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":700,"price":125.26,"value":87682.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":55144,"source":{"system":"sec-edgar","filing":"0001209191-23-016105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123016105/doc4.xml","form_type":"4"}},{"id":1971300,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-03-03T21:30:57.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":700,"price":3.7,"value":2590.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."}],"balance_after":55844,"source":{"system":"sec-edgar","filing":"0001209191-23-016105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123016105/doc4.xml","form_type":"4"}},{"id":2006352,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-17T21:31:13.000Z","date":"2023-02-17","kind":"exercise","acquired":false,"shares":13680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vested and became exercisable on November 5, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date."}],"balance_after":493045,"derivative":{"exercise_price":3.7,"expiration_date":"2030-12-17","underlying":"Common Stock","underlying_shares":13680},"source":{"system":"sec-edgar","filing":"0001209191-23-010972","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123010972/doc4.xml","form_type":"4"}},{"id":2006351,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-17T21:31:13.000Z","date":"2023-02-16","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vested and became exercisable on November 5, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date."}],"balance_after":506725,"derivative":{"exercise_price":3.7,"expiration_date":"2030-12-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-010972","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123010972/doc4.xml","form_type":"4"}},{"id":2006350,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-17T21:31:13.000Z","date":"2023-02-15","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date."}],"balance_after":308633,"derivative":{"exercise_price":2.9,"expiration_date":"2029-11-06","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-010972","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123010972/doc4.xml","form_type":"4"}},{"id":2006349,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-02-17T21:31:13.000Z","date":"2023-02-17","kind":"sale","acquired":false,"shares":13680,"price":125.1,"value":1711368.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":55144,"source":{"system":"sec-edgar","filing":"0001209191-23-010972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123010972/doc4.xml","form_type":"4"}},{"id":2006348,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-02-17T21:31:13.000Z","date":"2023-02-17","kind":"exercise","acquired":true,"shares":13680,"price":3.7,"value":50616.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."}],"balance_after":68824,"source":{"system":"sec-edgar","filing":"0001209191-23-010972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123010972/doc4.xml","form_type":"4"}},{"id":2006347,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-02-17T21:31:13.000Z","date":"2023-02-16","kind":"sale","acquired":false,"shares":25000,"price":119.87,"value":2996750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":55144,"source":{"system":"sec-edgar","filing":"0001209191-23-010972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123010972/doc4.xml","form_type":"4"}},{"id":2006346,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-02-17T21:31:13.000Z","date":"2023-02-16","kind":"exercise","acquired":true,"shares":25000,"price":3.7,"value":92500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."}],"balance_after":80144,"source":{"system":"sec-edgar","filing":"0001209191-23-010972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123010972/doc4.xml","form_type":"4"}},{"id":2006345,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-02-17T21:31:13.000Z","date":"2023-02-15","kind":"sale","acquired":false,"shares":25000,"price":119.42,"value":2985500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":55144,"source":{"system":"sec-edgar","filing":"0001209191-23-010972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123010972/doc4.xml","form_type":"4"}},{"id":2006344,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-02-17T21:31:13.000Z","date":"2023-02-15","kind":"exercise","acquired":true,"shares":25000,"price":2.9,"value":72500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person."}],"balance_after":80144,"source":{"system":"sec-edgar","filing":"0001209191-23-010972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123010972/doc4.xml","form_type":"4"}},{"id":2050351,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T20:39:19.000Z","date":"2023-01-17","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person in April 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date."}],"balance_after":333633,"derivative":{"exercise_price":2.9,"expiration_date":"2029-11-06","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-004136","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123004136/doc4.xml","form_type":"4"}},{"id":2050350,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-01-19T20:39:19.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":25000,"price":118.99,"value":2974750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person in April 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":55144,"source":{"system":"sec-edgar","filing":"0001209191-23-004136","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123004136/doc4.xml","form_type":"4"}},{"id":2050349,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2023-01-19T20:39:19.000Z","date":"2023-01-17","kind":"exercise","acquired":true,"shares":25000,"price":2.9,"value":72500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person in April 2022."}],"balance_after":80144,"source":{"system":"sec-edgar","filing":"0001209191-23-004136","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919123004136/doc4.xml","form_type":"4"}},{"id":2087418,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-12-13T20:32:44.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":128930,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option will vest on December 9, 2023, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date."}],"balance_after":128930,"derivative":{"exercise_price":110.2,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":128930},"source":{"system":"sec-edgar","filing":"0001209191-22-061088","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919122061088/doc4.xml","form_type":"4"}},{"id":2087417,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2022-12-13T20:32:44.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":37113,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of restricted stock units (\"RSUs\") granted under the Issuer's 2021 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting.  The award will vest and settle with respect to twenty-five percent (25%) of the total number of RSUs on December 9, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service with the Issuer through each vest date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a total of 2,631 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":55144,"source":{"system":"sec-edgar","filing":"0001209191-22-061088","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919122061088/doc4.xml","form_type":"4"}},{"id":2261294,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-20T19:11:49.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":246639,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the third anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":246639,"derivative":{"exercise_price":29.56,"exercise_date":"2025-05-20","expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":246639},"source":{"system":"sec-edgar","filing":"0001209191-22-031163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919122031163/doc4.xml","form_type":"4"}},{"id":2484840,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-03T19:02:37.000Z","date":"2021-12-01","kind":"exercise","acquired":false,"shares":15400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vested on September 9, 2020, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date."}],"balance_after":122531,"derivative":{"exercise_price":2.9,"expiration_date":"2029-11-06","underlying":"Common Stock","underlying_shares":15400},"source":{"system":"sec-edgar","filing":"0001209191-21-067992","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919121067992/doc4.xml","form_type":"4"}},{"id":2484839,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2021-12-03T19:02:37.000Z","date":"2021-12-01","kind":"exercise","acquired":true,"shares":15400,"price":2.9,"value":44660.0,"ownership":{"direct":true},"balance_after":15400,"source":{"system":"sec-edgar","filing":"0001209191-21-067992","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919121067992/doc4.xml","form_type":"4"}},{"id":2509868,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-16T21:03:46.000Z","date":"2021-11-14","kind":"grant","acquired":true,"shares":290000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest on November 14, 2022, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date."}],"balance_after":290000,"derivative":{"exercise_price":36.32,"expiration_date":"2031-11-13","underlying":"Common Stock","underlying_shares":290000},"source":{"system":"sec-edgar","filing":"0001209191-21-064933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718852/000120919121064933/doc4.xml","form_type":"4"}},{"id":3432478,"issuer":{"id":4363,"kind":"organization","name":"Bausch Health Companies Inc."},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"officer":true,"officer_title":"President, Salix"}}],"security":"Common Shares, No Par Value","published_at":"2019-08-21T20:15:13.000Z","date":"2019-08-19","kind":"sale","acquired":false,"shares":10773,"price":21.8343,"value":235220.9139,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.82 to $21.845 per share. The Reporting Person will provide to the Commission, the Issuer\nand any stockholder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range provided in this footnote."}],"balance_after":20756,"source":{"system":"sec-edgar","filing":"0001127602-19-027163","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885590/000112760219027163/form4.xml","form_type":"4"}},{"id":3478356,"issuer":{"id":4363,"kind":"organization","name":"Bausch Health Companies Inc."},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"officer":true,"officer_title":"President, Salix"}}],"security":"Common Shares, No Par Value","published_at":"2019-06-26T20:17:14.000Z","date":"2019-06-24","kind":"tax_withholding","acquired":false,"shares":1913,"price":23.82,"value":45567.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units."}],"balance_after":31529,"source":{"system":"sec-edgar","filing":"0001127602-19-022856","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885590/000112760219022856/form4.xml","form_type":"4"}},{"id":3535681,"issuer":{"id":4363,"kind":"organization","name":"Bausch Health Companies Inc."},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"officer":true,"officer_title":"President, Salix"}}],"security":"Common Shares, No Par Value","published_at":"2019-05-08T20:16:23.000Z","date":"2019-05-06","kind":"tax_withholding","acquired":false,"shares":746,"price":23.51,"value":17538.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units."}],"balance_after":33442,"source":{"system":"sec-edgar","filing":"0001127602-19-017744","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885590/000112760219017744/form4.xml","form_type":"4"}},{"id":3600409,"issuer":{"id":4363,"kind":"organization","name":"Bausch Health Companies Inc."},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"officer":true,"officer_title":"President, Salix"}}],"security":"Common Shares, No Par Value","published_at":"2019-03-12T20:38:38.000Z","date":"2019-03-08","kind":"tax_withholding","acquired":false,"shares":974,"price":23.56,"value":22947.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units."}],"balance_after":34188,"source":{"system":"sec-edgar","filing":"0001127602-19-011050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885590/000112760219011050/form4.xml","form_type":"4"}},{"id":3624667,"issuer":{"id":4363,"kind":"organization","name":"Bausch Health Companies Inc."},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"officer":true,"officer_title":"President, Salix"}}],"security":"Non-qualified Stock Options (right To Purchase)","published_at":"2019-03-01T22:13:07.000Z","date":"2019-02-27","kind":"grant","acquired":true,"shares":44290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in equal installments on each of the first three anniversaries of the date of grant."}],"balance_after":44290,"derivative":{"exercise_price":23.16,"expiration_date":"2029-02-27","underlying":"Common Shares, No Par Value","underlying_shares":44290},"source":{"system":"sec-edgar","filing":"0001127602-19-009255","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885590/000112760219009255/form4.xml","form_type":"4"}},{"id":3624666,"issuer":{"id":4363,"kind":"organization","name":"Bausch Health Companies Inc."},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"officer":true,"officer_title":"President, Salix"}}],"security":"Common Shares, No Par Value","published_at":"2019-03-01T22:13:07.000Z","date":"2019-02-27","kind":"grant","acquired":true,"shares":15221,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the award of restricted share units (\"RSUs\") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value (\"Common Shares\"), of Bausch Health Companies Inc. (\"Bausch Health\")."}],"balance_after":35162,"source":{"system":"sec-edgar","filing":"0001127602-19-009255","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885590/000112760219009255/form4.xml","form_type":"4"}},{"id":3698548,"issuer":{"id":4363,"kind":"organization","name":"Bausch Health Companies Inc."},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"officer":true,"officer_title":"President, Salix"}}],"security":"Common Shares, No Par Value","published_at":"2019-01-10T21:11:57.000Z","date":"2019-01-08","kind":"tax_withholding","acquired":false,"shares":1190,"price":21.25,"value":25287.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units."}],"balance_after":19941,"source":{"system":"sec-edgar","filing":"0001127602-19-001767","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885590/000112760219001767/form4.xml","form_type":"4"}}]}